Evorpacept (** No confirmed brand names or generic formulations identified. **)
Other Medications
Description
Evorpacept (also known as ALX148) is an experimental drug currently being studied in clinical trials for certain types of colorectal cancer. Specifically, it is being investigated for metastatic colorectal cancer that is microsatellite stable (MSS) and has not responded to at least two previous treatments. The drug is being tested in combination with two other drugs, cetuximab and pembrolizumab, to see if this combination is effective and safe for patients with this type of cancer. The trial is designed to evaluate the safety and effectiveness of this three-drug combination. It is being studied in an open-label, single-arm Phase 2 trial, meaning all participants and researchers know who is receiving the treatment, and the trial is comparing the treatment to historical data or standard of care rather than a placebo group.
Mechanism of Action
Evorpacept is being investigated as a potential treatment for MSS metastatic colorectal cancer. The specific way it works (its molecular target or mechanism of action) is not fully detailed in the available information, but it is being studied in combination with cetuximab (which targets the EGFR protein) and pembrolizumab (an immunotherapy drug that targets PD-1). The combination aims to target multiple pathways involved in tumor growth and immune evasion.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.